Van Enshi Pharmaceutical

Vanenshi Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to developing next-generation small molecule drugs for autoimmune and inflammatory diseases. The company's core focus lies in the development of highly selective kinase inhibitors, such as TYK2 and JAK1 inhibitors, to provide safer and more effective oral treatment options. Its lead candidate, VNS-101, is a potent and selective TYK2 inhibitor currently in Phase 2 development for plaque psoriasis. Beyond dermatology, Vanenshi is exploring applications for its pipeline in various immune-mediated conditions. The company is led by a team of experienced drug discovery professionals with backgrounds in global pharmaceutical organizations.